These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 25240016)

  • 1. Macrophage activation as an effector mechanism for cell-mediated immunity.
    Tam VC; Aderem A
    J Immunol; 2014 Oct; 193(7):3183-4. PubMed ID: 25240016
    [No Abstract]   [Full Text] [Related]  

  • 2. Science review: extracellular acidosis and the immune response: clinical and physiologic implications.
    Kellum JA; Song M; Li J
    Crit Care; 2004 Oct; 8(5):331-6. PubMed ID: 15469594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immune system: cells and molecules for the integration of self and non-self.
    Eichmann K
    Int J Sports Med; 1991 Jun; 12 Suppl 1():S2-4. PubMed ID: 1894393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanisms of macrophage activation and macrophage-mediated tumoricidal activity].
    Kiyotaki C
    Gan To Kagaku Ryoho; 1989 Oct; 16(10):3386-91. PubMed ID: 2508564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The defense mechanism and its weakening: the defense mechanism by cellular immunity].
    Hashimoto T
    Nihon Rinsho; 1986 Sep; 44(9):1965-71. PubMed ID: 3540365
    [No Abstract]   [Full Text] [Related]  

  • 6. Macrophages as effector cells of protective immunity in murine schistosomiasis. VI. T cell-dependent, lymphokine-mediated, activation of macrophages in response to Schistosoma mansoni antigens.
    James SL; Lazdins JK; Hieny S; Natovitz P
    J Immunol; 1983 Sep; 131(3):1481-6. PubMed ID: 6350456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microglia and tumor rejection.
    Frei K; Malipiero U; Piani D; Fontana A
    Neuropathol Appl Neurobiol; 1994 Apr; 20(2):206-8. PubMed ID: 8072666
    [No Abstract]   [Full Text] [Related]  

  • 8. Cell contact-mediated macrophage activation for antileishmanial defense. II. Identification of effector cell phenotype and genetic restriction.
    Sypek JP; Panosian CB; Wyler DJ
    J Immunol; 1984 Dec; 133(6):3351-7. PubMed ID: 6333458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell contact-mediated macrophage activation for antileishmanial defense. I. Lymphocyte effector mechanism that is contact dependent and noncytotoxic.
    Panosian CB; Sypek JP; Wyler DJ
    J Immunol; 1984 Dec; 133(6):3358-65. PubMed ID: 6208278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A T cell-independent mechanism of macrophage activation by interferon-gamma.
    Bancroft GJ; Schreiber RD; Bosma GC; Bosma MJ; Unanue ER
    J Immunol; 1987 Aug; 139(4):1104-7. PubMed ID: 3112223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTLA4Ig: effects on cellular and humoral immunity and macrophage activation.
    Schaub M; Stadlbauer TH; Sayegh MH
    Exp Nephrol; 1997; 5(5):370-4. PubMed ID: 9386972
    [No Abstract]   [Full Text] [Related]  

  • 12. Lung-phase immunity to Schistosoma mansoni. Flow cytometric analysis of macrophage activation states in vaccinated mice.
    Menson EN; Wilson RA
    J Immunol; 1989 Oct; 143(7):2342-8. PubMed ID: 2506284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-mediated killing: effector mechanisms and mediators.
    Ojcius DM; Young JD
    Cancer Cells; 1990 May; 2(5):138-45. PubMed ID: 2201340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of cell-mediated immunity as a strategy for vaccination against Schistosoma mansoni.
    James SL; Pearce EJ; Lanar D; Sher A
    Acta Trop Suppl; 1987 Jun; 12():50-4. PubMed ID: 3115075
    [No Abstract]   [Full Text] [Related]  

  • 15. Modulation of macrophage function by gamma-irradiation. Acquisition of the primed cell intermediate stage of the macrophage tumoricidal activation pathway.
    Lambert LE; Paulnock DM
    J Immunol; 1987 Oct; 139(8):2834-41. PubMed ID: 3116096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of T-cell unresponsiveness through serine-esterase inhibitors mediated enhanced lymphokine induced microbicidal activities in kala-azar.
    Bimal S; Lal SL; Lal CS; Singha UK; Saran R; Sen AB; Sahay VK
    Indian J Exp Biol; 1992 Jan; 30(1):54-6. PubMed ID: 1506018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The macrophage: a cellular factory at the interphase between iron and immunity for the control of infections.
    Theurl I; Fritsche G; Ludwiczek S; Garimorth K; Bellmann-Weiler R; Weiss G
    Biometals; 2005 Aug; 18(4):359-67. PubMed ID: 16158228
    [No Abstract]   [Full Text] [Related]  

  • 18. [Thirty years of cellular immunity].
    Finger H; Wirsing von König CH
    Immun Infekt; 1992 Aug; 20(4):125-7. PubMed ID: 1398732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophages as effector cells of protective immunity in murine schistosomiasis. V. Variation in macrophage schistosomulacidal and tumoricidal activities among mouse strains and correlation with resistance to reinfection.
    James SL; Skamene E; Meltzer MS
    J Immunol; 1983 Aug; 131(2):948-53. PubMed ID: 6863937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of monoclonal antibodies specific for macrophages at intermediate stages in the tumoricidal activation pathway.
    Paulnock DM; Lambert LE
    J Immunol; 1990 Jan; 144(2):765-73. PubMed ID: 2104906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.